SelectQuote Inc

SelectQuote Inc(SLQT)股票分析

$0.520

-0.019 (-3.70%)收盘时

Loading chart…
High
0.556
Open
0.531
VWAP
0.53
Vol
1.37M
Mkt Cap
463.49M
Low
0.513
Amount
722.73K
EV/EBITDA, TTM
3.73

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.

AI analysis of SelectQuote Inc (SLQT)

sell

SelectQuote Inc (SLQT) is not a good buy right now due to significant recent losses and declining revenue. The current price is $0.52, which is a staggering 75.93% lower than one year ago. Additionally, the stock has a very low RSI of 18.14, indicating it is oversold, but this also suggests a lack of buying momentum. The forward P/E ratio is extremely high at 66.67, which reflects overvaluation concerns given the company's recent performance. The main risk is the reported revenue decline of 6.7% in Q4 FY2026, which could further impact investor confidence and stock performance.

估值指标

The current forward P/E ratio for SelectQuote Inc (SLQT) is 66.67, compared to its 5-year average forward P/E of 0.07.

Forward P/E

Overvalued
5Y Average P/E
0.07
Current P/E
66.67
高估
44.54
低估
-44.40

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
1.20
Current EV/EBITDA
3.73
高估
53.51
低估
-51.11

Forward P/S

Fair
5Y Average P/S
0.37
Current P/S
0.07
高估
0.80
低估
-0.06

Alphio AI Price Scenarios for SLQT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SLQT

$2.27

情景价格

B

Base

Base · 50%SLQT

$2.16

情景价格

B

Bear

Bear · 25%SLQT

$1.66

情景价格

Whales holding SLQT

A

Abrams Bison Investments, L.L.C.

+ HoldingSLQT

+5.57%

3M Return

事件时间线

2026-08-25 (ET)

16:30:00

Major Averages Rise as Chip Stocks Benefit from Nvidia Earnings

12:30:00

Major Averages Slightly Higher, Chip Stocks Benefit from Nvidia Earnings

07:30:00

SelectQuote Q4 Revenue $321.7M, Below Consensus

07:30:00

Sees FY27 Adjusted EBITDA at $90M-$115M

2026-05-05 (ET)

07:30:00

SelectQuote Reports Q3 Revenue of $430.9M

资讯

SLQT FAQ — answered by Alphio AI

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

SelectQuote Inc (SLQT) is not a good buy right now due to significant recent losses and declining revenue. The current price is $0.52, which is a staggering 75.93% lower than one year ago. Additionally, the stock has a very low RSI of 18.14, indicating it is oversold, but this also suggests a lack of buying momentum. The forward P/E ratio is extremely high at 66.67, which reflects overvaluation concerns given the company's recent performance. The main risk is the reported revenue decline of 6.7% in Q4 FY2026, which could further impact investor confidence and stock performance.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始